171 related articles for article (PubMed ID: 35939202)
21. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
22. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
23. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
24. The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.
Xu G; Liu G; Xiong S; Liu H; Chen X; Zheng B
J Biol Chem; 2015 Feb; 290(9):5414-23. PubMed ID: 25583990
[TBL] [Abstract][Full Text] [Related]
25. Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.
Voelkel T; Andresen C; Unger A; Just S; Rottbauer W; Linke WA
Biochim Biophys Acta; 2013 Apr; 1833(4):812-22. PubMed ID: 23047121
[TBL] [Abstract][Full Text] [Related]
26. The ribosomal protein eL21 interacts with the protein lysine methyltransferase SMYD2 and regulates its steady state levels.
Khan MIK; Charles RCM; Ramachandran R; Gupta S; Govindaraju G; Mishra R; Rajavelu A; Coumar MS; Chavali S; Dhayalan A
Biochim Biophys Acta Mol Cell Res; 2021 Aug; 1868(9):119079. PubMed ID: 34147559
[TBL] [Abstract][Full Text] [Related]
27. SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Lai Y; Yang Y
Mol Cell Biochem; 2022 Sep; 477(9):2149-2159. PubMed ID: 32342276
[TBL] [Abstract][Full Text] [Related]
28. SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.
Boehm D; Jeng M; Camus G; Gramatica A; Schwarzer R; Johnson JR; Hull PA; Montano M; Sakane N; Pagans S; Godin R; Deeks SG; Krogan NJ; Greene WC; Ott M
Cell Host Microbe; 2017 May; 21(5):569-579.e6. PubMed ID: 28494238
[TBL] [Abstract][Full Text] [Related]
29. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
[TBL] [Abstract][Full Text] [Related]
30. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
31. SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Xu K; Ding J; Zhou L; Li D; Luo J; Wang W; Shang M; Lin B; Zhou L; Zheng S
Cells; 2022 Dec; 12(1):. PubMed ID: 36611819
[TBL] [Abstract][Full Text] [Related]
32. CD90
Xue BZ; Xiang W; Zhang Q; Wang HF; Zhou YJ; Tian H; Abdelmaksou A; Xue J; Sun MX; Yi DY; Xiong NX; Jiang XB; Zhao HY; Fu P
Stem Cell Res Ther; 2021 Jul; 12(1):394. PubMed ID: 34256854
[TBL] [Abstract][Full Text] [Related]
33. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T
Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
[TBL] [Abstract][Full Text] [Related]
34. PDLIM5 inhibits STUB1-mediated degradation of SMAD3 and promotes the migration and invasion of lung cancer cells.
Shi Y; Wang X; Xu Z; He Y; Guo C; He L; Huan C; Cai C; Huang J; Zhang J; Li Y; Zeng C; Zhang X; Wang L; Ke Y; Cheng H
J Biol Chem; 2020 Oct; 295(40):13798-13811. PubMed ID: 32737199
[TBL] [Abstract][Full Text] [Related]
35. Histone methyltransferase Smyd2 drives vascular aging by its enhancer-dependent activity.
Su Z; Su H; Xu J; Wei G; Qu L; Ni T; Yang D; Zhu Y
Aging (Albany NY); 2022 Dec; 15(1):70-91. PubMed ID: 36585926
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
Komatsu S; Imoto I; Tsuda H; Kozaki KI; Muramatsu T; Shimada Y; Aiko S; Yoshizumi Y; Ichikawa D; Otsuji E; Inazawa J
Carcinogenesis; 2009 Jul; 30(7):1139-46. PubMed ID: 19423649
[TBL] [Abstract][Full Text] [Related]
37. Structural insights into estrogen receptor α methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation.
Jiang Y; Trescott L; Holcomb J; Zhang X; Brunzelle J; Sirinupong N; Shi X; Yang Z
J Mol Biol; 2014 Oct; 426(20):3413-25. PubMed ID: 24594358
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of SET and MYND domain-containing protein 2 (
Zhang P; Ruan J; Weng W; Tang Y
Leuk Lymphoma; 2020 Feb; 61(2):437-444. PubMed ID: 31612757
[TBL] [Abstract][Full Text] [Related]
39. SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.
Zipin-Roitman A; Aqaqe N; Yassin M; Biechonski S; Amar M; van Delft MF; Gan OI; McDermott SP; Buzina A; Ketela T; Shlush L; Xie S; Voisin V; Moffat J; Minden MD; Dick JE; Milyavsky M
Oncotarget; 2017 Mar; 8(10):16712-16727. PubMed ID: 28187429
[TBL] [Abstract][Full Text] [Related]
40. The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias.
Brown MA; Edwards MA; Alshiraihi I; Geng H; Dekker JD; Tucker HO
Genes Immun; 2020 Feb; 21(2):119-130. PubMed ID: 32115575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
